Fact Source: Financial Supervisory Service DART / 2026-01-02
Disclosure Type: Other Management Matters (Voluntary Disclosure) (Major Management Matters of Subsidiaries)
💡 3-Second Summary
Celltrion’s U.S.-based subsidiary, Celltrion USA, Inc., has entered into a massive pharmaceutical contract manufacturing (CMO) agreement valued at approximately KRW 678.7 billion with global pharmaceutical firm Eli Lilly and Company.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Subsidiary Name: Celltrion USA, Inc. (Representative: Kim Bon-jung / Primary Business: Pharmaceutical Wholesale & Retail / Assets represent 2.46% of the parent’s consolidated assets)
- Counterparty: Eli Lilly and Company
- Date of Order & Decision: December 31, 2025
[Contract Details and Major Metrics]
- Contract Classification: Pharmaceutical Contract Manufacturing Agreement (CMO)
- Contract Value: KRW 678,707,700,000 (Approx. KRW 678.7B)
- This is calculated by applying the initial base exchange rate of USD/KRW 1,434.90 as of December 31, 2025, to the contract value of USD 473,000,000.
- Ratio to Revenue:
- Accounts for 19.08% of the parent company Celltrion’s recent annual revenue (KRW 3,557,303,554,371 based on the 2024 consolidated financial statements).
- Accounts for 462.53% of the subsidiary Celltrion USA, Inc.’s recent annual revenue (KRW 146,737,205,542 based on the 2024 separate financial statements).
- Contract Period: December 31, 2025 – December 31, 2029
- While the official contract span is 4 years, actual physical shipments are scheduled to take place over a 3-year period starting from Q2 2026 and ending in Q1 2029.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This voluntary disclosure represents a major operational milestone, confirming that Celltrion Group’s contract manufacturing (CMO) capabilities have been validated by one of the world’s leading pharmaceutical innovators. Because the counterparty is explicitly identified as Eli Lilly and Company and the total contract value represents nearly 19.08% of Celltrion’s consolidated revenue, this development carries a substantial potential impact that may structurally enhance the company’s long-term top-line expansion.
It is highly significant that the contracting party is Celltrion USA, Inc., a wholly-owned local subsidiary in the United States. Securing a CMO order valued at over 4.6 times its recent annual revenue of approximately KRW 146.7 billion is likely to significantly strengthen the subsidiary’s business scale and regional operational base.
Although specific margin dynamics and payment conditions remain confidential, the structured 3-year delivery timeline from Q2 2026 to Q1 2029 implies that this revenue stream will be recognized incrementally over the medium term. While exchange rate fluctuations present a variable that could adjust the ultimate KRW-denominated value, securing a direct, long-term supply volume with a global big pharma partner signals improved fundamental earnings stability.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion has secured an exceptional CMO contract exceeding KRW 670 billion through its U.S. subsidiary, partnering with global industry leader Eli Lilly. Unlike many supply contracts that restrict partner identities, the transparent disclosure of Eli Lilly and Company as the counterparty greatly enhances market visibility and analytical trust. With physical deliveries scheduled to begin in Q2 2026, this contract will likely serve as a major driver for consolidated top-line momentum starting this year. The reliable cash flows generated by this milestone will also provide solid capital support as management proceeds with its proactive shareholder value-up initiatives.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
